((自动化翻译由路透提供，请见免责声明 ))
9月17日 - ** Oruka Therapeutics ORKA.O> 股价上涨 4.87% 至 27.18 美元
** 券商Leerink Partners开始对Oruka Therapeutics进行评级，评级为 "跑赢大盘"，目标价44美元。
** 称该药物开发商为 "慢性皮肤病领域的杀手鲸"
** 券商称，随着该公司针对价值 400 亿美元的银屑病及相关疾病市场机会，推进潜在的巨头候选药物管线，其股价将跑赢大盘
** 该公司的抗体ORKA-001的效率将达到或超过艾伯维 的Skyrizi。
** 公司将于 2025 年第一季度开始 ORKA-001 的早期试验，用于治疗银屑病--一种会导致皮肤发炎和鳞屑的慢性自身免疫性疾病。
** ORKA 的股价在过去一年里翻了一番多
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.